NASDAQ:MEDP - Medpace Stock Price, Price Target & More

Medpace trades on the NASDAQ under the ticker symbol "MEDP."

Medpace Holdings (NASDAQ:MEDP) announced its earnings results on Monday, February, 26th. The company reported $0.39 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.38 by $0.01. The firm earned $99.45 million during the quarter, compared to analyst estimates of $97.25 million. Medpace had a net margin of 8.97% and a return on equity of 10.55%. Medpace's revenue was up 4.3% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.35 EPS. View Medpace's Earnings History.

Medpace is scheduled to release their next quarterly earnings announcement on Monday, April, 30th 2018. View Earnings Estimates for Medpace.

Medpace issued an update on its FY18 earnings guidance on Monday, February, 26th. The company provided earnings per share (EPS) guidance of $1.82 to $1.93 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.80. The company issued revenue guidance of $412 million to $428 million, compared to the consensus revenue estimate of $423.58 million.

7 brokers have issued 1-year target prices for Medpace's stock. Their forecasts range from $35.00 to $42.00. On average, they expect Medpace's stock price to reach $36.75 in the next twelve months. View Analyst Ratings for Medpace.

Medpace saw a decrease in short interest in the month of March. As of March 15th, there was short interest totalling 426,813 shares, a decrease of 31.6% from the February 28th total of 624,254 shares. Based on an average daily volume of 257,372 shares, the days-to-cover ratio is presently 1.7 days. Approximately 5.0% of the shares of the stock are sold short.

Some companies that are related to Medpace include Intrexon (XON), National Research (NRCIB), National Research (NRCIA), Sorrento Therapeutics (SRNE), Pieris Pharmaceuticals (PIRS), Viralytics (VRACY), Luna Innovations (LUNA), Anavex Life Sciences (AVXL), Senomyx (SNMX) and Cleveland BioLabs (CBLI).

(MEDP) raised $150 million in an IPO on Thursday, August 11th 2016. The company issued 7,000,000 shares at a price of $20.00-$23.00 per share. Jefferies, Credit Suisse, UBS Investment Bank and Wells Fargo Securities acted as the underwriters for the IPO and Baird and William Blair were co-managers.

Media coverage about MEDP stock has trended somewhat positive this week, according to Accern Sentiment. The research firm rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Medpace earned a coverage optimism score of 0.17 on Accern's scale. They also assigned media headlines about the company an impact score of 45.80 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of MEDP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of MEDP stock can currently be purchased for approximately $37.70.

Medpace has a market capitalization of $1.34 billion and generates $436.15 million in revenue each year. The company earns $39.12 million in net income (profit) each year or $1.52 on an earnings per share basis. Medpace employs 2,500 workers across the globe.

Medpace's mailing address is 5375 MEDPACE WAY, CINCINNATI OH, 45227. The company can be reached via phone at 513-579-9911 or via email at [email protected]